# Cooper Companies, Inc.

**COO**

Nasdaq; healthcare; SIC 3851, Ophthalmic Goods; CIK 0000711404

**C**

**middle fifth of 367 graded peers in healthcare**

rank 208 of 367; percentile 56.6; sampling error 2.5 points; lower is stronger

A B C D E

**C, the tortoise**



| Scoreboard | |
|---|---|
| **Profitability** | C<br>percentile 51.6 |
| **Solvency** | C<br>percentile 49.6 |
| **Growth and financing** | C<br>percentile 49.0 |
| **Reliability** | 0.94 AUC<br>filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025 |
| **Peer failure rate** | 0.52% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | over $2.67B assets<br>total assets $12.4B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: distress |
| **Inputs computable** | 12 of 14 |
| **Graded from** | filings received through Dec 5, 2025<br>346 days before the rescan; latest periodic filing 10-Q received Sep 9, 2026 |
| **Last close** | $62.66<br>2026-11-13; market equity $11.9B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Dec 5, 2025*

The Cooper Companies, Inc. (Cooper, we or the Company), is a leading global medical device company focused on helping people experience life's beautiful moments. Headquartered in San Ramon, California, Cooper sells products in over 130 countries and positively impacts over fifty million lives each year. Cooper operates through two business segments, CooperVision and CooperSurgical. Our two business segments elevate standards of care with products and services in the fields of vision, fertility and women's health. For financial information relating to these business segments, refer to Note 12. Business Segment Information in Item 8.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 51.6** | | | | | | |
| Gross profitability | 21.6% | 32.3% | | 62.9 | 365 | 2025-10-31 |
| Return on invested capital | 4.3% | 9.3% | | 63.0 | 74 | 2025-10-31 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Accruals ratio | (3.4%) | (6.6%) | | 69.5 | 799 | 2025-10-31 |
| Gross margin stability, five years | 0.8 pts | 2.8 pts | | 10.8 | 242 | 2025-10-31 |
| **Solvency, sleeve percentile 49.6** | | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | | |
| Altman Z double-prime | 4.99 | (0.31) | | 18.6 | 743 | 2025-10-31 |
| Net debt to EBITDA | 2.21x | 1.82x | | 56.8 | 75 | 2025-10-31 |
| Interest coverage | not computable | (4.51x) | | | | |
| *latest aligned inputs end 2023-10-31; latest annual assets end 2025-10-31* | | | | | | |
| Current ratio | 1.89x | 2.96x | | 73.4 | 825 | 2025-10-31 |
| **Growth and financing, sleeve percentile 49.0** | | | | | | |
| Revenue growth, three-year compound | 7.3% | 10.1% | | 55.4 | 411 | 2025-10-31 |
| Free cash flow growth, three-year compound | (1.3%) | 11.0% | | 74.5 | 95 | 2025-10-31 |
| Reinvestment rate | 11.0% | 37.1% | | 62.1 | 104 | 2025-10-31 |
| Asset growth, three years | 2.6% | 2.3% | | 45.8 | 693 | 2025-10-31 |
| Net share issuance, one year | (1.8%) | 2.4% | | 7.0 | 627 | 2025-12-01 |

## Among 367 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 203 | Abbott Laboratories (ABT) | 55.2 | C | |
| 204 | Teladoc Health, Inc. (TDOC) | 55.5 | C | fortress balance sheet |
| 205 | ELI Lilly & Co. (LLY) | 55.7 | C | |
| 206 | Neuronetics, Inc. (STIM) | 56.0 | C | |
| 207 | AdaptHealth Corp. (AHCO) | 56.3 | C | |
| 208 | Cooper Companies, Inc. (COO) | 56.6 | C | |
| 209 | Inogen Inc. (INGN) | 56.8 | C | fortress balance sheet |
| 210 | Aquestive Therapeutics, Inc. (AQST) | 57.1 | C | |
| 211 | Prestige Consumer Healthcare Inc. (PBH) | 57.4 | C | |
| 212 | Option Care Health, Inc. (OPCH) | 57.7 | C/D | |
| 213 | Mannkind Corp. (MNKD) | 57.9 | C/D | |

## What the price implies

*at the 2026-11-13 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (19.1%) | (1.5%) | 37 |
| Distance from 52-week high | (25.7%) | (32.0%) | 55 |
| EBIT to enterprise value | 5.0% | (1.8%) | 81 |
| Free cash flow yield | 3.6% | (1.0%) | 74 |
| Book value to price | 0.70 | 0.29 | 77 |
| Sales to price | 0.34 | 0.29 | 54 |
| Composite equity issuance, five years | (3.3%) | 19.1% | 23 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Relative strength against the sector, log excess return | (0.38) | (0.18) | 37 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score 5 of 9, period end 2025-10-31** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | pass |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | pass |
| Current ratio improved | fail |
| No new shares issued | pass |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $154.7M |
| Operating cash flow, four quarters | $1.0B |
| Months of runway | not finite |
| Days since last periodic filing | 68 (10-Q received Sep 9, 2026) |
| Median daily dollar volume, 63 sessions | $155.7M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $2.7B | 2025-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 2 | assets | us-gaap:Assets | $12.4B | 2025-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 3 | operating income | us-gaap:OperatingIncomeLoss | $682.9M | 2025-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 4 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $566.5M | 2025-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 5 | income tax | us-gaap:IncomeTaxExpenseBenefit | $191.6M | 2025-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 6 | total debt | us-gaap:LongTermDebtAndCapitalLeaseObligations | $2.5B | 2025-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 7 | book equity | us-gaap:StockholdersEquity | $8.2B | 2025-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 8 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $110.6M | 2025-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 9 | total debt | us-gaap:LongTermDebtAndCapitalLeaseObligations | $2.6B | 2024-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 10 | book equity | us-gaap:StockholdersEquity | $8.1B | 2024-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 11 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $107.6M | 2024-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 12 | net income | us-gaap:NetIncomeLoss | $374.9M | 2025-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 13 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $796.1M | 2025-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 14 | assets | us-gaap:Assets | $12.3B | 2024-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $4.1B | 2025-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 16 | gross profit | us-gaap:GrossProfit | $2.6B | 2024-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 17 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $3.9B | 2024-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 18 | gross profit | us-gaap:GrossProfit | $2.4B | 2023-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 19 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $3.6B | 2023-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 20 | gross profit | us-gaap:GrossProfit | $2.1B | 2022-10-31 | 2024-12-06 | 10-K | 24-000074 |
| 21 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $3.3B | 2022-10-31 | 2024-12-06 | 10-K | 24-000074 |
| 22 | gross profit | us-gaap:GrossProfit | $2.0B | 2021-10-31 | 2023-12-08 | 10-K | 23-000072 |
| 23 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $2.9B | 2021-10-31 | 2023-12-08 | 10-K | 23-000072 |
| 24 | current assets | us-gaap:AssetsCurrent | $2.1B | 2025-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 25 | current liabilities | us-gaap:LiabilitiesCurrent | $1.1B | 2025-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 26 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | $7.6B | 2025-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 27 | liabilities | us-gaap:Liabilities | $4.2B | 2025-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 28 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $377.4M | 2025-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 29 | operating income | us-gaap:OperatingIncomeLoss | $533.1M | 2023-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 30 | interest expense | us-gaap:InterestExpense | $105.3M | 2023-10-31 | 2023-12-08 | 10-K | 23-000072 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 31 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $362.4M | 2025-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 32 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $709.3M | 2024-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 33 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $421.2M | 2024-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 34 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $607.5M | 2023-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 35 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $392.5M | 2023-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 36 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $692.4M | 2022-10-31 | 2024-12-06 | 10-K | 24-000074 |
| 37 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $242.0M | 2022-10-31 | 2024-12-06 | 10-K | 24-000074 |
| 38 | current assets | us-gaap:AssetsCurrent | $2.0B | 2024-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 39 | current liabilities | us-gaap:LiabilitiesCurrent | $1.0B | 2024-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 40 | assets | us-gaap:Assets | $11.7B | 2023-10-31 | 2025-12-05 | 10-K | 25-055615 |
| 41 | assets | us-gaap:Assets | $11.5B | 2022-10-31 | 2024-12-06 | 10-K | 24-000074 |
| 42 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 195,978,026 | 2025-12-01 | 2025-12-05 | 10-K | 25-055615 |
| 43 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 199,582,626 | 2024-11-29 | 2024-12-06 | 10-K | 24-000074 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.